Fundraising FoxF2G
13 known investors
Find your way into F2G
Sign up to see every warm intro you have to F2G
- Paths you didn't know you had: your email and LinkedIn already hold routes to the F2G team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
F2G develops medicines to treat serious fungal diseases where existing therapies have failed or are ineffective. The company operates an early access program to provide investigational therapies to qualified patients with life-threatening fungal infections who are ineligible for clinical trials or lack suitable alternative treatment options.
Investors · 13
How we know: Advent Life Sciences's portfolio page · funding news · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Aisling Capital's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: AMR Action Fund's portfolio page · funding news · Not right? Tell us
How we know: Astellas Venture Management LLC's portfolio page · Not right? Tell us
How we know: Brace Pharma's portfolio page · Not right? Tell us
How we know: Sofinnova Partners's portfolio page · a partner's Signal profile · funding news · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Sunstone Capital's portfolio page · funding news · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: open dataset · 5k.vc investor directory · Not right? Tell us
How we know: a partner's Signal profile · funding news · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: a partner's Signal profile · funding news · Not right? Tell us
Also in the syndicate · 2
Funding
SEC filings, press & company announcements$160M disclosed across 2 of 3 rounds · 2016–2024
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does F2G do?
- F2G develops medicines to treat serious fungal diseases where existing therapies have failed or are ineffective. The company operates an early access program to provide investigational therapies to qualified patients with life-threatening fungal infections who are ineligible for clinical trials or lack suitable alternative treatment options.
- Who are F2G's investors?
- F2G's investors include Advent Life Sciences, Aisling Capital, AMR Action Fund, Astellas Venture Management LLC, Brace Pharma, Sofinnova Partners, Sunstone Capital, Abingworth and 3 more.
- How much funding has F2G raised?
- F2G has disclosed $160M raised across 2 of its 3 known rounds.